Interferon-alpha is effective in HTLV-I-associated myelopathy A multicenter, randomized, double-blind, controlled trial

摘要: A double-blind, multi-center study was performed on patients with HTLV-I-associated myelopathy (HAM) to evaluate the therapeutic effect of treatment natural interferon-alpha (HLBI). Forty-eight HAM were enrolled and treated either 0.3 MU (n = 15), 1.0 17), or 3.0 16) HLBI for 28 days. Clinical evaluation included motor dysfunction, urinary disturbances, changes neurologic signs. The frequency response judged as excellent good 4 weeks after starting therapy completion 7.1% (1 14) 8.3% 12) in 0.3-MU group, 23.5% (4 17) 26.7% 15) 1.0-MU 66.7% (10 61.5% (8 13) 3.0-MU group. benefit group significantly higher than There no significant difference incidence symptomatic side effects between groups. Abnormal laboratory data obtained some groups; however, schedule could be continued most patients. These results suggest that may safely every day favorable clinical effects.